- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02128282
Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma
A Phase I/II Study of CX-4945 in Combination With Gemcitabine and Cisplatin in the Frontline Treatment of Patients With Cholangiocarcinoma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Protein kinase CK2 is a constitutively active serine/threonine kinase with a long history as a pro-survival, anti-apoptotic kinase. Given the wide spread overexpression of CK2 in multiple cancers and its role in multiple non-oncogenic processes required to sustain the cancer phenotype, a selective inhibitor of CK2 is an attractive targeted approach to treating cancer.
CX-4945 is a tetracyclic, small molecule carboxylate acid salt that exhibits potent and highly selective inhibition of CK2. Protein kinase CK2 is also known to play an important role in the DNA damage repair mechanisms of cancer cells, and this study of CX-4945 in combination with gemcitabine plus cisplatin will determine if inhibition of CK2, in conjunction with the use of chemotherapy drugs, will result in improved clinical outcomes for patients with non-resectable cholangiocarcinoma.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Seoul, Korea, Republic of
- Seoul National University Hospital
-
Seoul, Korea, Republic of
- Samsung Medical Center
-
Seoul, Korea, Republic of
- Severance Hospital, Yonsei University Health System
-
-
Songpa-gu
-
Seoul, Songpa-gu, Korea, Republic of, 138-736
- Asan Medical Center
-
-
-
-
-
Kaohsiung City, Taiwan
- Chang-Gung Memorial Hospital - Kaohsiung Branch
-
Taichung City, Taiwan
- China Medical University Hospital
-
Tainan City, Taiwan
- National Cheng Kung University Hospitals
-
Taipei, Taiwan
- Taipei Veterans General Hospital
-
Taipei City, Taiwan
- National Taiwan University Hospital
-
Taoyuan City, Taiwan
- Chang-Gung Memorial Hospital - Linkou Branch
-
-
-
-
Arizona
-
Scottsdale, Arizona, United States, 85259-5499
- Mayo Clinic
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- University of Colorado- Denver
-
-
Florida
-
Jacksonville, Florida, United States, 32224
- Mayo Clinic
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
Texas
-
Dallas, Texas, United States, 75246
- Texas Oncology - Baylor Charles A. Sammons Cancer Center
-
Tyler, Texas, United States, 75702
- Texas Oncology-Tyler
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Presence of an unresectable hepatobiliary mass or metastatic disease (consistent with cholangiocarcinoma, as evidenced by histology or cytology (augmented by fluorescence in situ hybridization (FISH) where appropriate), for which treatment with gemcitabine plus cisplatin is intended. Intrahepatic and extrahepatic cholangiocarcinoma patients may be enrolled.
- For patients enrolled in the Dose Escalation Phase, one or more tumors measurable on radiograph or CT scan, or evaluable disease defined as non-measurable lesions per RECIST v. 1.1 (e.g., malignant ascites). All patients enrolled to the Randomized Study Phase must have measurable disease only.
Laboratory data as specified below:
- Hematology: Absolute neutrophil count (ANC) >1,500 cells/mm3, platelet count >100,000 cells/ mm.cu. and hemoglobin > 9 g/dL
- Hepatic: bilirubin <1.5 X Upper Limit of Normal (ULN); alkaline phosphatase (ALP), alanine aminotransferase (ALT) or aspartate aminotransferase (AST) < 5.0 X ULN
- Renal: serum creatinine within normal limits (WNL), defined as within 25% of the institution's stated reference range, or a calculated creatinine clearance >45 mL/min/1.73 m. sq. for patients with abnormal, increased, creatinine levels.
- Coagulation: International Normalized Ratio (INR) < 1.5 times normal, activated Partial Thromboplastin Time (aPTT) < 1.5 times normal. Patients receiving therapeutic doses of anticoagulant therapy may be considered eligible for the trial if INR and aPTT are within the acceptable therapeutic limits for the institution.
- Eastern Cooperative Oncology Group (ECOG) Performance Status 0 - 1.
Exclusion Criteria:
- A history of prior systemic treatment with gemcitabine or cisplatin. At least six months must have elapsed if gemcitabine or cisplatin was administered in an adjuvant treatment setting. Patients enrolled in the Expansion Cohort, Exploratory Cohorts, and the Randomized Phase must not have received prior systemic chemotherapies, including chemoradiation therapy for cholangiocarcinoma.
- Seizure disorders requiring anticonvulsant therapy.
- Known brain metastases (unless previously treated and well controlled for a period of at least 3 months).
- Major surgery other than diagnostic surgery, within 4 weeks prior to the first dose of test drug, minor surgery including diagnostic surgery within 2 weeks (14 days) excluding central IV port placements and needle aspirate/core biopsies. Radio frequency ablation or transcatheter arterial chemoembolization within 6 weeks prior to the first dose of test drug.
- Treatment with radiation therapy or surgery within one month prior to study entry.
- Treatment with chemotherapy or investigational drugs within 21 days prior to the screening visit. Acute toxicities from prior therapy must have resolved to Grade ≤ 1 above baseline.
- Patients with a history of another malignancy within 3 years of the baseline visit. (Patients with cutaneous carcinomas or in-situ carcinomas will be considered for study entry on a case-by-case basis).
- Concurrent severe or uncontrolled medical disease (i.e., systemic infection, diabetes, hypertension, coronary artery disease, congestive heart failure).
- Active symptomatic fungal, bacterial and/or viral infection including active HIV or viral (A, B or C) hepatitis which would not permit the patient to be managed according to the protocol.
- Difficulty with swallowing or an active malabsorption syndrome.
- Chronic diarrhea (excess of 2-3 stools/day above normal frequency).
- Gastrointestinal diseases including ulcerative colitis, Crohn's disease, or hemorrhagic coloproctitis.
- History of gastric or small bowel surgery involving any extent of gastric or small bowel resection.
- Clinically significant bleeding event within the last 3 months, unrelated to trauma, or underlying condition that would be expected to result in a bleeding diathesis.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Escalation CX-4945 plus Cis/Gem
CX-4945 capsules at the combination MTD on Days 0, 1 and 2, and Days 7, 8 and 9. PLUS Cisplatin 25 mg/m.sq. by IV infusion on Days 1 and 8. PLUS Gemcitabine 1,000 mg/m.sq. by IV infusion on Days 1 and 8. On a 21-day cycle. |
API powder-in-capsule in 200 mg strength.
25 mg/m.sq.
administered by IV infusion on Days 1 and 8 of a 21-day cycle.
Other Names:
1,000 mg/m.sq.
administered by IV infusion on Days 1 and 8 of a 21-day cycle.
Other Names:
|
Active Comparator: Cisplatin plus Gemcitabine
Cisplatin 25 mg/m.sq.
by IV infusion on Days 1 and 8. PLUS Gemcitabine 1,000 mg/m.sq.
by IV infusion on Days 1 and 8. On a 21-day cycle.
|
25 mg/m.sq.
administered by IV infusion on Days 1 and 8 of a 21-day cycle.
Other Names:
1,000 mg/m.sq.
administered by IV infusion on Days 1 and 8 of a 21-day cycle.
Other Names:
|
Experimental: 10-day CX-4945 plus Cis/Gem
CX-4945 capsules at 1000mg/BID, 10-day continuous dosing (Day 0 through Day 9).
PLUS Cisplatin 25 mg/m.sq.
by IV infusion on Days 1 and 8. PLUS Gemcitabine 1,000 mg/m.sq.
by IV infusion on Days 1 and 8. On a 21-day cycle.
|
API powder-in-capsule in 200 mg strength.
25 mg/m.sq.
administered by IV infusion on Days 1 and 8 of a 21-day cycle.
Other Names:
1,000 mg/m.sq.
administered by IV infusion on Days 1 and 8 of a 21-day cycle.
Other Names:
|
Experimental: 21-day CX-4945 plus Cis/Gem
CX-4945 capsules at 1000mg/BID, 21-day continuous dosing PLUS Cisplatin 25 mg/m.sq.
by IV infusion on Days 1 and 8. PLUS Gemcitabine 1,000 mg/m.sq.
by IV infusion on Days 1 and 8. On a 21-day cycle.
|
API powder-in-capsule in 200 mg strength.
25 mg/m.sq.
administered by IV infusion on Days 1 and 8 of a 21-day cycle.
Other Names:
1,000 mg/m.sq.
administered by IV infusion on Days 1 and 8 of a 21-day cycle.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Tolerated Dose (MTD) of CX-4945 when used in combination with gemcitabine plus cisplatin. (Phase 1)
Time Frame: Cycle 1, 1 Full cycle up to twenty-one (21) days
|
The Maximum Tolerated Dose of CX-4945 will be determined from safety observations during the first cycle, as the CX-4945 dose is escalated in cohorts of three patients in combination with standard gemcitabine plus cisplatin.
|
Cycle 1, 1 Full cycle up to twenty-one (21) days
|
Comparison of the Progression-free survival (PFS) between the test and the control arms using Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1 (Phase 2)
Time Frame: From date of randomization to date of progression or death from any cause up to 52 weeks.
|
Tumor measurements will be compared to baseline every six weeks, and the PFS will be determined using RECIST v. 1.1.
|
From date of randomization to date of progression or death from any cause up to 52 weeks.
|
Recommended Phase II dose (RP2D) and schedule of CX-4945 in combination with gemcitabine plus cisplatin (Phase I)
Time Frame: Cycle 1, 1 Full cycle up to twenty-one (21) days
|
The recommended Phase II dose and schedule of CX-4945 will be determined from safety observations during the first cycle, as the CX-4945 dose is administered 1000mg BID in 10-day continuous or 21-day continuous cohorts in combination with standard gemcitabine plus cisplatin.
|
Cycle 1, 1 Full cycle up to twenty-one (21) days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Comparison of the Overall Response Rate (ORR) between the test and the control arms using Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1
Time Frame: From date of randomization to date of progression or death from any cause up to 52 weeks.
|
Tumor measurements will be compared to baseline, and the ORR will be determined using RECIST v. 1.1
|
From date of randomization to date of progression or death from any cause up to 52 weeks.
|
Comparison of the number of patient who transition to surgical resection
Time Frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months
|
The number of patients in the chemotherapy arm versus CX-4945 plus chemotherapy arm who transition to surgical resection will be compared.
|
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months
|
Comparison of the Overall Survival (OS) between the test and the control arms
Time Frame: From date of randomization to date of death from any cause up to 52 weeks.
|
Time to event is observed during treatment and followed up every 3 months after patient withdraw from treatment.
|
From date of randomization to date of death from any cause up to 52 weeks.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Mitesh Borad, M.D., Mayo Clinic
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Adenocarcinoma
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Cholangiocarcinoma
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Gemcitabine
Other Study ID Numbers
- S4-13-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cholangiocarcinoma
-
M.D. Anderson Cancer CenterActive, not recruitingStage III Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Metastatic Intrahepatic Cholangiocarcinoma | Locally Advanced Intrahepatic CholangiocarcinomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)Not yet recruitingStage III Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Unresectable Intrahepatic Cholangiocarcinoma | Locally Advanced Intrahepatic Cholangiocarcinoma | Oligometastatic Intrahepatic CholangiocarcinomaUnited States
-
RedHill Biopharma LimitedCompletedCholangiocarcinoma | Cholangiocarcinoma Non-resectable | Cholangiocarcinoma, Perihilar | Cholangiocarcinoma, Extrahepatic | Cholangiocarcinoma, IntrahepaticUnited States
-
RedHill Biopharma LimitedAvailableCholangiocarcinoma | Cholangiocarcinoma Non-resectable | Cholangiocarcinoma, Perihilar | Cholangiocarcinoma, Extrahepatic | Cholangiocarcinoma, Intrahepatic
-
National Cancer Institute (NCI)CompletedStage III Intrahepatic Cholangiocarcinoma AJCC v8 | Gallbladder Carcinoma | Metastatic Cholangiocarcinoma | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Unresectable CholangiocarcinomaUnited States
-
Emory UniversityNational Cancer Institute (NCI); National Institutes of Health (NIH); CelgeneActive, not recruitingResectable Cholangiocarcinoma | Stage IB Intrahepatic Cholangiocarcinoma AJCC v8 | Stage II Intrahepatic Cholangiocarcinoma AJCC v8 | Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8United States
-
Emory UniversityNational Cancer Institute (NCI)WithdrawnStage II Intrahepatic Cholangiocarcinoma AJCC v8 | Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Resectable Intrahepatic Cholangiocarcinoma | Stage 0 Intrahepatic Cholangiocarcinoma AJCC v8 | Stage I Intrahepatic Cholangiocarcinoma AJCC v8United States
-
AIO-Studien-gGmbHServierCompletedCholangiocarcinoma Non-resectable | Cholangiocarcinoma of the Gallbladder | Cholangiocarcinoma Metastatic | Cholangiocarcinoma AdvancedGermany
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Active, not recruitingMetastatic Cholangiocarcinoma | Unresectable Cholangiocarcinoma | Advanced CholangiocarcinomaUnited States
-
University of Kansas Medical CenterNational Cancer Institute (NCI)RecruitingStage III Intrahepatic Cholangiocarcinoma AJCC v8 | Metastatic Cholangiocarcinoma | Locally Advanced Cholangiocarcinoma | Stage III Hilar Cholangiocarcinoma AJCC v8 | Stage IV Hilar Cholangiocarcinoma AJCC v8 | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Recurrent CholangiocarcinomaUnited States
Clinical Trials on CX-4945
-
Cylene PharmaceuticalsUnknownMultiple MyelomaUnited States
-
Senhwa Biosciences, Inc.Active, not recruitingCarcinoma, Basal CellUnited States
-
Cylene PharmaceuticalsUnknownBreast Cancer | Multiple Myeloma | Advanced Solid Tumors | Inflammatory Breast Cancer | Castleman's DiseaseUnited States
-
Senhwa Biosciences, Inc.Completed
-
University of ArizonaSenhwa Biosciences, Inc.TerminatedCoronavirusUnited States
-
Pediatric Brain Tumor ConsortiumNational Cancer Institute (NCI); American Lebanese Syrian Associated Charities...SuspendedMedulloblastoma, ChildhoodUnited States
-
Senhwa Biosciences, Inc.Not yet recruitingCommunity-acquired Pneumonia | Influenza With Pneumonia | SARS-CoV-2 -Associated PneumoniaTaiwan
-
Chris Recknor, MDCompleted
-
CytomX TherapeuticsWithdrawnSolid Tumor, AdultUnited States
-
CytomX TherapeuticsCompletedNeoplasms | Breast Cancer | Breast Neoplasms | Breast Neoplasms, Triple-Negative | Breast Neoplasms, Hormone Receptor Positive/HER2 NegativeUnited States, Spain, Korea, Republic of